US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AgomAb Therapeutics

13.94

-1.0200-6.82%

Post-market: 14.200.2600+1.87%18:07 EDT

Volume:106.79K

Turnover:1.53M

Market Cap:686.52M

PE:-3.09

High:16.40

Open:14.91

Low:13.75

Close:14.96

52wk High:17.82

52wk Low:8.75

Shares:49.25M

Float Shares:13.84M

Volume Ratio:0.47

T/O Rate:0.77%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.5143

EPS(LYR):-168.1598

ROE:-39.22%

ROA:-20.58%

PB:6.40

PE(LYR):-0.08

Loading ...

Overview Company News Filings

Agomab Therapeutics NV Director Ohad Hammer files initial beneficial ownership statement

Agomab Therapeutics NV files Form 3 initial beneficial ownership statement for Chief Medical Officer Philippe Constantin Wiesel

Agomab Therapeutics NV Director Felice Isabel Verduyn-van Weegen Files Initial Beneficial Ownership Statement

Agomab Therapeutics NV Director Angelika Martha Jahreis Files Initial Beneficial Ownership Statement

Agomab Therapeutics Nv : Van Lanschot Kempen Initiates Coverage With Buy Rating; Price Target $33

THOMSON REUTERS

Morgan Stanley Sticks to Their Buy Rating for AgomAb Therapeutics NV ADR (AGMB)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/stock/AGMB/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"AGMB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","market":"US","secType":"STK","nameCN":"AgomAb Therapeutics","latestPrice":13.94,"timestamp":1789070400000,"preClose":14.96,"halted":0,"volume":106791,"hourTrading":{"tag":"盘后","latestPrice":14.2,"preClose":13.94,"latestTime":"18:07 EDT","volume":322,"amount":4586.08,"timestamp":1789078074659,"change":0.26,"changeRate":0.018651,"amplitude":0.018651},"delay":0,"changeRate":-0.06818181818181827,"floatShares":13836000,"shares":49248000,"eps":-4.51426,"marketStatus":"Closed","change":-1.02,"latestTime":"09-10 16:00:00 EDT","open":14.91,"high":16.4,"low":13.75,"amount":1526161.394055,"amplitude":0.177139,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.51426,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789113600000},"marketStatusCode":5,"adr":0,"listingDate":1770354000000,"exchange":"NASDAQ","adjPreClose":14.96,"preHourTrading":{"tag":"盘前","latestPrice":14.96,"preClose":14.96,"latestTime":"09:19 EDT","volume":1,"amount":14.96,"timestamp":1789046389661,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":14.2,"preClose":13.94,"latestTime":"18:07 EDT","volume":322,"amount":4586.08,"timestamp":1789078074659,"change":0.26,"changeRate":0.018651,"amplitude":0.018651},"volumeRatio":0.466227},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","floatShares":13836000,"roa":"-20.58%","roe":"-39.22%","lyrEps":-168.159829,"volumeRatio":0.466227,"shares":49248000,"dividePrice":0,"high":16.4,"amplitude":0.177139,"preClose":14.96,"low":13.75,"week52Low":8.75,"pbRate":"6.40","week52High":17.82,"institutionHeld":0,"latestPrice":13.94,"eps":-4.51426,"divideRate":0,"volume":106791,"delay":0,"ttmEps":-4.51426,"open":14.91,"prevYearClose":16,"prevWeekClose":15.78,"prevMonthClose":13.17,"prevQuarterClose":12.98,"fiveDayClose":13.66,"twentyDayClose":14.11,"sixtyDayClose":10},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AGMB\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AGMB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AGMB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":8,"updateTime":1787716800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AGMB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AGMB","date":"2026-09-09","current":-3.087992,"percent":0.376712,"low":-14.725744,"twenty":-12.174048,"median":-8.973278,"eighty":-7.908684,"high":-6.52172,"avg":-9.617178,"sd":2.208524,"marketCap":734287307},"quantilePoints":[{"date":"2026-02-06","current":-14.293959,"twenty":-14.293959,"median":-14.293959,"eighty":-14.293959,"marketCap":779788464},{"date":"2026-02-13","current":-13.901135,"twenty":-14.202947,"median":-13.85921,"eighty":-13.805127,"marketCap":763217959},{"date":"2026-02-20","current":-13.975141,"twenty":-14.020702,"median":-13.811207,"eighty":-13.436782,"marketCap":760781120},{"date":"2026-02-27","current":-14.297833,"twenty":-14.274685,"median":-13.837477,"eighty":-13.631029,"marketCap":780275831},{"date":"2026-03-06","current":-12.944797,"twenty":-14.315694,"median":-13.869306,"eighty":-13.479283,"marketCap":692549629},{"date":"2026-03-13","current":-12.71107,"twenty":-14.294734,"median":-13.805127,"eighty":-12.961754,"marketCap":677928595},{"date":"2026-03-20","current":-11.600011,"twenty":-14.274685,"median":-13.584093,"eighty":-12.695924,"marketCap":618957093},{"date":"2026-03-27","current":-10.84065,"twenty":-14.216331,"median":-13.160447,"eighty":-12.395453,"marketCap":578505566},{"date":"2026-04-02","current":-10.748527,"twenty":-14.066263,"median":-13.052487,"eighty":-11.414439,"marketCap":574119256},{"date":"2026-04-10","current":-9.193391,"twenty":-13.930737,"median":-12.827934,"eighty":-10.709469,"marketCap":497602513},{"date":"2026-04-17","current":-10.018749,"twenty":-13.86294,"median":-12.650405,"eighty":-9.901184,"marketCap":545851924},{"date":"2026-04-24","current":-9.622204,"twenty":-13.825362,"median":-12.457995,"eighty":-9.650988,"marketCap":521483535},{"date":"2026-05-01","current":-7.206485,"twenty":-13.809991,"median":-11.744798,"eighty":-9.486381,"marketCap":528794052},{"date":"2026-05-08","current":-7.639457,"twenty":-13.779732,"median":-11.111376,"eighty":-9.258769,"marketCap":562411874},{"date":"2026-05-15","current":-7.446972,"twenty":-13.702513,"median":-10.748527,"eighty":-8.300034,"marketCap":543697644},{"date":"2026-05-22","current":-7.434647,"twenty":-13.568448,"median":-10.364346,"eighty":-8.115636,"marketCap":538772846},{"date":"2026-05-29","current":-7.796965,"twenty":-13.4527,"median":-9.998785,"eighty":-7.794875,"marketCap":568321631},{"date":"2026-06-05","current":-8.053102,"twenty":-13.287949,"median":-9.784729,"eighty":-7.758816,"marketCap":585558422},{"date":"2026-06-12","current":-6.750851,"twenty":-13.127527,"median":-9.578953,"eighty":-7.536224,"marketCap":486569993},{"date":"2026-06-18","current":-6.929006,"twenty":-13.073014,"median":-9.501773,"eighty":-7.448225,"marketCap":497404547},{"date":"2026-06-26","current":-9.2886,"twenty":-13.035188,"median":-9.467948,"eighty":-7.458553,"marketCap":661400304},{"date":"2026-07-02","current":-8.166663,"twenty":-12.965993,"median":-9.467948,"eighty":-7.479819,"marketCap":584573463},{"date":"2026-07-10","current":-8.975013,"twenty":-12.944797,"median":-9.309036,"eighty":-7.532768,"marketCap":641701114},{"date":"2026-07-17","current":-8.479177,"twenty":-12.71107,"median":-9.193391,"eighty":-7.541408,"marketCap":606735052},{"date":"2026-07-24","current":-8.981683,"twenty":-12.707304,"median":-9.020605,"eighty":-7.554336,"marketCap":638746235},{"date":"2026-07-31","current":-8.723327,"twenty":-12.661785,"median":-8.978348,"eighty":-7.610114,"marketCap":628157921},{"date":"2026-08-07","current":-9.22434,"twenty":-12.557349,"median":-9.00807,"eighty":-7.636377,"marketCap":664847662},{"date":"2026-08-14","current":-8.931525,"twenty":-12.519309,"median":-9.035172,"eighty":-7.716456,"marketCap":686763011},{"date":"2026-08-21","current":-8.496488,"twenty":-12.423423,"median":-8.981683,"eighty":-7.781927,"marketCap":661400304},{"date":"2026-08-28","current":-8.778373,"twenty":-12.380686,"median":-8.974146,"eighty":-7.796268,"marketCap":681591974},{"date":"2026-09-04","current":-9.428222,"twenty":-12.300242,"median":-8.931525,"eighty":-7.867232,"marketCap":730347469},{"date":"2026-09-09","current":-9.480184,"twenty":-12.174048,"median":-8.973278,"eighty":-7.908684,"marketCap":734287307}],"updateTime":1789085525580},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AGMB\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620264410","title":"Agomab Therapeutics NV Director Ohad Hammer files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620264410","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620264410?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:02","pubTimestamp":1773864177,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics reported an initial statement of beneficial ownership by director Ohad Hammer. The filing listed a stock option for 27,921 common shares. The option has an exercise price of USD 14.26.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agomab Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL98LGY6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620126441","title":"Agomab Therapeutics NV files Form 3 initial beneficial ownership statement for Chief Medical Officer Philippe Constantin Wiesel","url":"https://stock-news.laohu8.com/highlight/detail?id=2620126441","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620126441?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:02","pubTimestamp":1773864168,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics NV files Form 3 initial beneficial ownership statement for Chief Medical Officer Philippe Constantin Wiesel. Agomab Therapeutics reported an initial statement of beneficial ownership by Philippe Constantin Wiesel, its chief medical officer. The filing listed stock options covering 21,732 common shares with an exercise price of USD 1.13. It also listed stock options covering 155,433 common shares with an exercise price of USD 0.0005.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agomab Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL7l047W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620726445","title":"Agomab Therapeutics NV Director Felice Isabel Verduyn-van Weegen Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620726445","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620726445?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:02","pubTimestamp":1773864154,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics reported an initial statement of beneficial ownership for director Felice Isabel Verduyn-van Weegen. The filing listed a stock option to buy 32,700 common shares. The option had an exercise price of USD 14.26. The option expiration date was Jan. 15, 2036.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agomab Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDLbglz9D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620264460","title":"Agomab Therapeutics NV Director Angelika Martha Jahreis Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620264460","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620264460?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:02","pubTimestamp":1773864149,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics reported an initial statement of beneficial ownership for director Angelika Jahreis. The filing listed stock options covering 94,438 common shares with an exercise price of USD 3.1. It also reported stock options for 31,505 common shares with an exercise price of USD 14.26.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agomab Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL4WJWZN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620125813","title":"Agomab Therapeutics Nv : Van Lanschot Kempen Initiates Coverage With Buy Rating; Price Target $33","url":"https://stock-news.laohu8.com/highlight/detail?id=2620125813","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620125813?lang=en_us&edition=fundamental","pubTime":"2026-03-18 19:53","pubTimestamp":1773834818,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nFWN40613U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618992931","title":"Morgan Stanley Sticks to Their Buy Rating for AgomAb Therapeutics NV ADR (AGMB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618992931","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618992931?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:36","pubTimestamp":1773139003,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Judah Frommer from Morgan Stanley maintained a Buy rating on AgomAb Therapeutics NV ADR, with a price target of $28...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanley-sticks-to-their-buy-rating-for-agomab-therapeutics-nv-adr-agmb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanley-sticks-to-their-buy-rating-for-agomab-therapeutics-nv-adr-agmb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGMB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":46,"code":"91000000","status":"200"}]}}